Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: An Observational Study in A Chinese Population.
Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: An Observational Study in A Chinese Population.
复制标题
DOI：
10.1038/srep30673
复制
发表时间：
2016-08-01
影响因子：
4.6
通讯作者：
Wu N
中科院分区：
文献类型：
--
作者：
Ling Z;Jin C;Xie T;Cheng Y;Li L;Wu N
现有证据表明，肠道微生物群的改变可能与人类免疫缺陷病毒1（HIV-1）感染患者的微生物易位和全身炎症增加密切相关。我们通过平行条形码454-焦磷酸测序对67名HIV-1感染患者（32名接受高效抗逆转录病毒治疗[HAART]，35名HAART初治）和16名中国健康对照者的粪便微生物群进行了分析，作为肠道微生物群的代表。我们发现，α多样性指数在健康对照组和HIV-1感染者之间没有显著差异。HIV-1感染者中厚壁菌/拟杆菌的比例显著增加。几种关键的细菌性大肠杆菌类型，包括普雷沃氏菌属，在HIV-1感染的患者中普遍存在;而嗜乳杆菌属、梭菌属XIVb、小杆菌属和巨单胞菌属与全身炎症细胞因子显著相关。在短期有效的HAART治疗后，HIV-1的病毒载量降低;然而，粪便微生物群的多样性和组成并没有完全恢复。在接受HAART的HIV-1感染者中，这种生态失调仍然存在。我们的详细分析表明，粪便微生物群的失调可能在HIV-1感染中起着积极的作用。因此，可以为靶向微生物群的治疗提供新的见解，以减缓HIV疾病的进展并降低HIV-1感染患者中肠道相关疾病的风险。
The available evidence suggests that alterations in gut microbiota may be tightly linked to the increase in microbial translocation and systemic inflammation in patients with human immunodeficiency virus 1 (HIV-1) infection. We profiled the fecal microbiota as a proxy of gut microbiota by parallel barcoded 454-pyrosequencing in 67 HIV-1-infected patients (32 receiving highly active antiretroviral therapy [HAART] and 35 HAART naïve) and 16 healthy controls from a Chinese population. We showed that α-diversity indices did not differ significantly between the healthy control and HIV-1-infected patients. The ratio of Firmicutes/Bacteroidetes increased significantly in HIV-1-infected patients. Several key bacterial phylotypes, including Prevotella, were prevalent in HIV-1-infected patients; whereas Phascolarctobacterium, Clostridium XIVb, Dialister and Megamonas were significantly correlated with systemic inflammatory cytokines. After short-term, effective HAART, the viral loads of HIV-1 were reduced; however, the diversity and composition of the fecal microbiota were not completely restored. and the dysbiosis remained among HIV-1-infected subjects undergoing HAART. Our detailed analysis demonstrated that dysbiosis of fecal microbiota might play an active role in HIV-1 infection. Thus, new insights may be provided into therapeutics that target the microbiota to attenuate the progression of HIV disease and to reduce the risk of gut-linked disease in HIV-1-infected patients.